Documentos relacionados

1. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
2. Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men.
3. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.
4. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
5. Re: Rates of Prostate Surgery and Acute Urinary Retention for Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride.
6. Editorial Comment to Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
7. Re: Long-Term Dutasteride Therapy in Men with Benign Prostatic Hyperplasia Alters Glucose and Lipid Profiles and Increases Severity of Erectile Dysfunction.
8. Controlled Delivery of Dutasteride Using Dissolvable Microarrays: Initial Formulation and In Vivo Evaluation.
9. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
10. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.